Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors

NCT04294576 is registered in ClinicalTrials.gov with BJ Bioscience, Inc. as lead sponsor.

NCT NCT04294576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04294576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
BJ Bioscience, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
December 4, 2019
Completion date
October 22, 2024
Enrollment
92 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced/metastatic solid tumors